Matthew Simon

Senior Scientist

Denali Therapeutics


Matt received his PhD in neuroscience at Oregon Health & Science University, studying brain-CSF interactions in aging and neurodegeneration. He has been at Denali Therapeutics for 5 years, characterizing in vivo models of neurodegeneration and their use in biomarker discovery and drug pharmacodynamic profiling. His works has spanned a range of brain-penetrant drug modalities, most recently including antibody-oligonucleotide conjugates.